We are live on ! Find out more
AAP

Aristotle Atlantic Partners Portfolio holdings

AUM $2.14B
1-Year Est. Return 37.01%
This Fund
S&P 500
This Quarter Est. Return
+5.83%
1 Year Est. Return
+37.01%
3 Year Est. Return
+123.74%
5 Year Est. Return
+154.13%
10 Year Est. Return
–
AUM
$288M
AUM Growth
+$11.3M
Cap. Flow
-$1.59M
Cap. Flow %
-0.55%
Top 10 Hldgs %
61.3%
Holding
95
New
4
Increased
57
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
TECH icon
Bio-Techne
TECH
+$2.61M
2
MSFT icon
Microsoft
MSFT
+$1.81M
3
GPN icon
Global Payments
GPN
+$1.78M
4
SAGE
Sage Therapeutics
SAGE
+$1.37M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$951K

Top Sells

Rank Stock Value
1
MON
Monsanto Co
MON
+$7.03M
2
SHPG
Shire pic
SHPG
+$2.89M
3
GILD icon
Gilead Sciences
GILD
+$2.4M
4
EVHC
Envision Healthcare Holdings Inc
EVHC
+$1.54M
5
MUR icon
Murphy Oil
MUR
+$1.51M

Sector Composition

Rank Sector Weight
1 Healthcare 33.61%
2 Energy 17.8%
3 Industrials 17.78%
4 Technology 10.38%
5 Financials 6.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
1
Merck
MRK
$315B
$42.2M 14.63%
728,370
– –
XOM icon
2
ExxonMobil
XOM
$611B
$27.3M 9.46%
329,696
-4,350
-1% -$347K
UNP icon
3
Union Pacific
UNP
$179B
$22.7M 7.86%
160,000
– –
MUR icon
4
Murphy Oil
MUR
$5.28B
$18.5M 6.42%
548,637
-49,000
-8% -$1.51M
CELG
5
DELISTED
Celgene Corp
CELG
$14M 4.86%
176,392
+2,731
+2% +$227K
ROP icon
6
Roper Technologies
ROP
$36.6B
$12.3M 4.28%
44,697
+526
+1% +$145K
JPM icon
7
JPMorgan Chase
JPM
$907B
$11M 3.83%
105,995
+2,845
+3% +$312K
TMO icon
8
Thermo Fisher Scientific
TMO
$198B
$11M 3.83%
53,260
+736
+1% +$156K
AME icon
9
Ametek
AME
$54.3B
$10.5M 3.64%
145,549
+1,872
+1% +$139K
PCH
10
DELISTED
PotlatchDeltic
PCH
$7.22M 2.5%
142,065
– –
MSFT icon
11
Microsoft
MSFT
$2.93T
$6.96M 2.42%
70,665
+18,717
+36% +$1.81M
BA icon
12
Boeing
BA
$169B
$6.22M 2.16%
18,529
+1,075
+6% +$370K
AMT icon
13
American Tower
AMT
$79.2B
$5.77M 2%
40,000
– –
PH icon
14
Parker-Hannifin
PH
$120B
$5.46M 1.89%
35,024
+460
+1% +$78.4K
GILD icon
15
Gilead Sciences
GILD
$167B
$4.43M 1.53%
62,500
-34,000
-35% -$2.4M
TECH icon
16
Bio-Techne
TECH
$11.2B
$4.01M 1.39%
108,440
+68,440
+171% +$2.61M
AAPL icon
17
Apple
AAPL
$4.9T
$3.79M 1.32%
82,036
+7,696
+10% +$349K
COO icon
18
Cooper Companies
COO
$14B
$3.77M 1.31%
64,000
– –
EOG icon
19
EOG Resources
EOG
$74.5B
$3.46M 1.2%
27,778
+845
+3% +$98.2K
PF
20
DELISTED
Pinnacle Foods, Inc.
PF
$3.41M 1.18%
52,371
+2,390
+5% +$147K
MUSA icon
21
Murphy USA
MUSA
$11.4B
$3.22M 1.12%
43,413
-10,145
-19% -$701K
GPN icon
22
Global Payments
GPN
$21.3B
$3.2M 1.11%
28,750
+15,750
+121% +$1.78M
AGN
23
DELISTED
Allergan plc
AGN
$3.02M 1.05%
18,155
+1,205
+7% +$193K
IDXX icon
24
Idexx Laboratories
IDXX
$44.8B
$2.95M 1.02%
13,526
– –
ALGN icon
25
Align Technology
ALGN
$12.7B
$2.74M 0.95%
8,022
-1,099
-12% -$328K
1
2 3 4

Similar funds

SC
SouthState Corp Winter Haven, Florida $2.14B AUM 18.39% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.15B AUM 25.5% 1-Year Est. Return
NAAA
New Age Alpha Advisors Rye, New York $2.15B AUM 27.2% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
GHA
GW Henssler & Associates Kennesaw, Georgia $2.12B AUM 20.77% 1-Year Est. Return
BCM
Basswood Capital Management New York $2.12B AUM 19.53% 1-Year Est. Return
MA
Montag & Associates Atlanta, Georgia $2.15B AUM 20.86% 1-Year Est. Return

Aristotle Atlantic Partners's Q2 2018 Portfolio in Review

As of Q2 2018, Aristotle Atlantic Partners held 95 positions worth $288M, up 4.1% from $277M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Aristotle Atlantic Partners's Q2 2018 filing shows 4 new, 57 increased, 8 reduced and 12 closed positions. Its largest new stake was Sage Therapeutics: 8,700 shares worth $1.36M. The largest sale was Monsanto Co, an estimated $7.03M.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, down from 34% a quarter earlier, followed by Energy and Industrials.

  • Aristotle Atlantic Partners's largest Q2 2018 buy was Sage Therapeutics: 8,700 shares worth $1.36M.
  • Aristotle Atlantic Partners added most to Bio-Techne in Q2 2018, an estimated $2.61M increase.
  • Aristotle Atlantic Partners's biggest Q2 2018 reduction was Gilead Sciences, cutting an estimated $2.4M.
  • Aristotle Atlantic Partners fully exited Monsanto Co in Q2 2018, selling an estimated $7.03M.
  • Aristotle Atlantic Partners's ten largest holdings make up 61% of its $288M portfolio in Q2 2018.
  • Aristotle Atlantic Partners opened 4 new positions and closed 12 in Q2 2018.
  • Aristotle Atlantic Partners's portfolio value rose 4.1% quarter-over-quarter to $288M.

Based on Aristotle Atlantic Partners's 13F filing for Q2 2018, filed 14 Aug 2018.